Previous 10 | Next 10 |
Gainers: [[PGNY]] +7.9%. [[XELB]] +7.0%. [[IDYA]] +6.9%. [[LSCC]] +6.6%. [[DKNG]] +6.0%.Losers: [[SPNE]] -3.8%. [[DBVT]] -3.4%. [[SYBX]] -3.0%. [[SESN]] -2.6%. [[DSEY]] -2.5%. For further details see: PGNY, XELB, SPNE and SYBX among after-hours movers
IDEAYA Biosciences (IDYA) has spiked as much as ~7.0% in the post-market after announcing a pre-market press release and a webcast scheduled for tomorrow to discuss the clinical data from a clinical study involving patients with metastatic uveal melanoma (MUM), a type of...
IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib (IDE196) Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma PR Newswire SOUTH SAN FRANCISCO, Calif. , April 15, 2021 /PRNewswire/ -- IDEAYA B...
IDEAYA Biosciences (IDYA) has begun dosing the first patient in a Phase 1 trial for its experimental cancer therapy IDE397 in patients with solid tumors with methylthioadenosine (“MTAP”) phosphorylase (MTAP) deletion.IDE397 has received IND clearance from the FDA ...
IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP-Deletion Solid Tumors - IDE397 demonstrates significant single-agent anti-tumor activity in a 40-plus MTAP-deletion PDX study, including tumor regressions, across major s...
IDEAYA Biosciences (IDYA) announced dose expansion of the ongoing Phase 1/2 study evaluating the combination of IDE196 and binimetinib in metastatic uveal melanoma ("MUM").The company expects to enroll ~40 patients for the IDE196 and binimetinib combination arm in the trial conducte...
IDEAYA Biosciences (IDYA): Q4 GAAP EPS of -$0.18 beats by $0.04.Revenue of $10.6M beats by $2.68M.Shares -0.34% PM.Press Release For further details see: IDEAYA Biosciences EPS beats by $0.04, beats on revenue
IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity - Targeting enrollment of approximately 40 patients in the IDE196 and binimetinib clinical combination Phase 1/2 study in MUM ...
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update - Initiated Phase 1 clinical trial for IDE397, a potential best-in-class MAT2A inhibitor for patients having tumors with MTAP-deletion - Planning to present data at AACR in Ap...
IDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG, and Kinase Inhibitor IDE196 PR Newswire SOUTH SAN FRANCISCO, Calif. , March 11, 2021 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synth...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NASDAQ Market:
IDEAYA Biosciences Inc. Website:
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , July 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery an...
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...